Dear All, I wrote on 3 Jan 2020 (link) about the NIAID contract intended to establish an innovative Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). The formal solicitation has now gone live and can be found here. The deadline for applications is 16 Mar 2020. Get to it! In parallel, there is a superb Wall Street Journal podcast dated 13 Jan 2020 about

This newsletter is part of a series — here are the links to Part 1, Part 2, Part 3, (this one is Part 4), and Part 5.  Dear All, We had fun in Feb 2020 discussing whether an antibacterial compound discovered using machine learning was a drug or just a chemical. Building on that conversation, the lab that wrote the

Note: For those of you with an interest in developing bacterial vaccines, the results of Pfizer’s failed STRIVE S. aureus vaccine have now appeared in print along with an excellent editorial commentary. Deep sigh on this one — please see the updated prior newsletter for the links and the full story.  This newsletter is part

Dear All, As a follow up to the glorious cacophony of the events occurring right at the end of April, Kevin Outterson and I made time to discuss all that has happened. The PASTEUR Act reintroduced, the AMR House Subcommittee hearing, the European Commission proposals, the CARB-X Annual Report, FDA approval of the first microbiome-based therapeutic …